Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Mark Dennis, PhD Fellow at Denali Therapeutics


Building on 35 years of experience in protein and antibody
engineering while a Principal Scientist at Genentech, Mark is
currently a Fellow at Denali Therapeutics providing strategic
direction and guidance for the development of protein
therapeutics targeting neurological diseases. While at
Genentech, Mark developed a practical method to deliver
biotherapeutics across the blood-brain barrier, established that
association with albumin could increase the serum half-life of
biotherapeutics and was a key member of teams establishing
early Antibody-drug conjugate (ADC) and T-cell Dependent
Bispecific (TDC) technologies for oncology. Mark has
authored over 60 papers and contributed to over 30 granted

Agenda Sessions